ALIGOS THERAPEUTICS INC (ALGS)
US01626L1052 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.36M | 13.91M 219.04% | 15.529M 11.64% | 3.82M -75.40% | 1.36M -64.40% | -100.00% | 243.79M | 523.05M 114.55% | 848.37M 62.20% | 1.198B 41.21% | ||
| EBITDA YoY % growth | -125.3M -31.77% | -95.27M 23.97% | -80.768M 15.22% | -95.88M -18.71% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -128.32M -31.17% | -97.58M 23.96% | -82.327M 15.63% | -94.957M -15.34% | -117.01M -23.22% | -137.538M -17.54% | -163.871M -19.15% | -86.755M 47.06% | 249.85M 388.00% | 536.59M 114.76% | 833.38M 55.31% | |
| Operating Margin | -2,943.12% | -701.51% | -530.15% | -2,485.78% | -8,603.65% | N/A | N/A | -35.59% | 47.77% | 63.25% | 69.56% | |
| EPS YoY % growth | -80.00 34.19% | -56.50 29.38% | -39.75 29.65% | -10.75 72.97% | -12.16 -13.12% | -13.40 -10.27% | -15.99 -19.33% | -5.64 64.73% | 27.60 589.33% | 58.99 113.71% | 72.62 23.12% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.55 53.70% | -2.74 50.11% | -2.91 -463.80% | -3.04 0.99% | -3.03 -18.96% |
| Revenue Q2Q % growth | 441.997K -78.00% | 339.997K -65.52% | 339.997K -67.96% | 339.997K -73.21% | 339.997K -23.08% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -24.175M 7.36% | -26.071M -18.26% | -28.032M -6.13% | -30.305M -50.54% | -32.601M -34.85% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -3.07 70.05% | -2.20 | -0.87 | -39.56% |
| Q2 2024 Q2Q % growth | 0.80 107.44% | -4.08 | 4.88 | 119.61% |
| Q1 2024 Q2Q % growth | -5.50 58.49% | -4.85 | -0.66 | -13.52% |
| Q4 2023 Q2Q % growth | -5.50 56.86% | -6.89 | 1.38 | 20.12% |
| Q3 2023 Q2Q % growth | -10.25 6.82% | -12.11 | 1.86 | 15.38% |
| Q2 2023 Q2Q % growth | -10.75 8.51% | -12.62 | 1.87 | 14.83% |
| Q1 2023 Q2Q % growth | -13.25 36.90% | -12.37 | -0.88 | -7.14% |
| Q4 2022 Q2Q % growth | -12.75 42.70% | -12.04 | -0.71 | -5.93% |
| Q3 2022 Q2Q % growth | -11.00 43.59% | -14.79 | 3.79 | 25.63% |
| Q2 2022 Q2Q % growth | -11.75 40.51% | -17.00 | 5.25 | 30.88% |
| Q1 2022 Q2Q % growth | -21.00 -13.51% | -18.55 | -2.45 | -13.20% |
| Q4 2021 Q2Q % growth | -22.25 18.35% | -21.11 | -1.14 | -5.38% |
| Q3 2021 Q2Q % growth | -19.50 92.91% | -20.76 | 1.26 | 6.06% |
| Q2 2021 Q2Q % growth | -19.75 | -20.57 | 0.82 | 3.99% |
| Q1 2021 Q2Q % growth | -18.50 | -22.95 | 4.45 | 19.39% |
| Q4 2020 Q2Q % growth | -27.25 | -21.04 | -6.21 | -29.53% |
| Q3 2020 Q2Q % growth | -275.00 | -19.89 | -255.11 | -1,282.60% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 1.269M -60.82% | 339.997K | 929.003K | 273.24% |
| Q2 2024 Q2Q % growth | 1.061M -84.59% | 1.061M | % | |
| Q1 2024 Q2Q % growth | 986K -63.79% | 986K | % | |
| Q4 2023 Q2Q % growth | 2.009M -43.25% | 1.632M | 377K | 23.10% |
| Q3 2023 Q2Q % growth | 3.239M -21.19% | 2.55M | 689K | 27.02% |
| Q2 2023 Q2Q % growth | 6.886M 86.61% | 6.886M | % | |
| Q1 2023 Q2Q % growth | 2.723M 5.95% | 2.723M | % | |
| Q4 2022 Q2Q % growth | 3.54M 856.76% | 1.754M | 1.786M | 101.82% |
| Q3 2022 Q2Q % growth | 4.11M 166.88% | 765K | 3.345M | 437.25% |
| Q2 2022 Q2Q % growth | 3.69M 138.06% | 3.69M | % | |
| Q1 2022 Q2Q % growth | 2.57M 182.42% | 2.57M | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -1287.04% | -56.89% | -59.02% |
| Revenue | 0% | N/A | 12.72% | 38.76% |